Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226050 · ClinicalTrials.gov registry record · Phase 2
CLF065 for Chronic Pouchitis
A Phase 2 study of Pouchitis, sponsored by Calibr, a division of Scripps Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07226050: Recruiting Phase 2 study of Pouchitis, sponsored by Calibr, a division of Scripps Research.
NCT07226050 is a Phase 2 study of Pouchitis that is actively recruiting participants, run by Calibr, a division of Scripps Research. The registered enrollment target is 20 participants, below the 24-participant average among 5 other Pouchitis trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226050, a Phase 2 study of Pouchitis, is actively recruiting participants, sponsored by Calibr, a division of Scripps Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is to evaluate investigational compound CLF065 as a treatment for adult patients with chronic pouchitis. The goals are to establish the safety, feasibility and efficacy of weekly dosing of long acting CLF065 versus placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CLF065
Study Locations (1)
California
- Phillip Fleshner, M.D. Inc - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
What NCT07226050 shows while recruiting
NCT07226050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 24-participant average among 5 other Pouchitis trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Pouchitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07226050 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07226050 about?
NCT07226050 is a clinical study titled "CLF065 for Chronic Pouchitis". This clinical trial is to evaluate investigational compound CLF065 as a treatment for adult patients with chronic pouchitis. The goals are to establish the safety, feasibility and efficacy of weekly dosing of long acting CLF065 versus placebo.
What is the current status of trial NCT07226050?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-03-05. Estimated completion is 2027-06.
What conditions does trial NCT07226050 study?
This clinical trial studies the following conditions: Pouchitis.
What interventions are being tested in trial NCT07226050?
The interventions under investigation include: Placebo (DRUG), CLF065 (DRUG).
Who is sponsoring clinical trial NCT07226050?
This trial is sponsored by Calibr, a division of Scripps Research, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226050 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pouchitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
RECRUITING · Phase 4
-
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
RECRUITING · Early Phase 1
-
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
RECRUITING · Phase 4
-
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
COMPLETED · NA
-
Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI